Fig. 7

The effects of Obatoclax on the liver metastasis of colorectal cancer in vivo. (A) Representative IVIS luciferase in vivo images of mice with CT26-Luc2 cells injected in the spleen and treated with normal saline (NS), 2 mg/kg or 5 mg/kg Obatoclax (n = 6). The images obtained on indicated days were quantified with a unified fluorescence scale. (B) Summary data of the fluorescence intensity of the mice treated on day 0, 7 and 13. *P < 0.05. (C) Images of liver from the tumor bearing mice on day 13. The images obtained were quantified with a unified fluorescence scale. (D) Summary data of fluorescence intensity of the liver. **P < 0.01, *** P < 0.001. (E) Summary data of the liver weight. **P < 0.01, *** P < 0.001. (F) The fold change (FC) in mRNA expression of MAOS and MAPS signature genes in the CT26 cell line before and after treatment with Obatoclax. FC values were calculated by converting the normalized average log2 values of gene expression levels before and after treatment with Obatoclax at concentrations of 0.01 µM and 0.3 µM